410.337.4500

PAST  TRIALS

Horizon RVO: “FVF3426g (HORIZON

An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability Of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) Who Have Completed The Treatment Phase Of A Genentech Sponsored Ranibizumab Study

 

RIDE-FVF4168g

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement (CSME-CI) secondary to diabetes mellitus (Type 1 or 2).

 

Marina-FVF2598g

An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study

 

Focus FVF2428g 

This is an open label multicenter extension study for participants who have completed one of the following studies: FVF2428g (NCT00056823), FVF2587g (NCT00061594) or FVF2598g (NCT0056823). Cohort 1 includes patients with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD).

 

Sailor- FVF3689g

A Phase IIIb, Multicenter Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

 

RAP                                                                                                                 

FVF3423s: Phase 1 Study of Intravitreal Lucentis for the Treatment of Stage 1 and 2 Retinal Angiomatous Proliferations

 

WIRB-Protocol-#20052536                                                                                                                       

Comparison of Intravitreal Versus Anterior Sub-Tenon’s Injection of Triamcinolone Acetonide for Refractory Diabetic Macular Edema, A Randomized Clinical Trial

 

WIRB-Protocol-#20051556                                                                                                                                       

An Observational Case Series of Patients Who Underwent Surgery for Full Thickness Macular Holes and Assessed Pre- and Post-Operatively With the Micro Perimeter (MP1)

 

CLEAR-IT1

A Phase I, Dose-Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreal VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration

 

EOP1004H

A Phase II/III Randomized, Double Masked, Controlled, Dose-Ranging, Multi-Center Comparative Trial, in Parallel Groups, To Establish the Safety and Efficacy of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks For 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration (AMD)

 

AMD-02-99

A Multicenter, Prospective, Randomized, Double-Masked Study Comparing the Safety and Efficacy of Membrane Differential Filtration to a Placebo Treatment in Patients with Non-Exudative Age-Related Macular Degeneration

 

VGFT-OD-0508

The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD. This is a double masked, prospective, randomized study in which five groups of approximately 30 patients meeting the eligibility criteria will be randomly assigned in a balanced ratio to receive a series of intravitreal (IVT) injections of VEGF Trap into the study eye at 4- or 12 -week intervals over a 12-week period.

 

TG-MV-006                                                                                                                            

A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion

 

AG3340-801                                                                                                                                                                    

A Phase II, Randomized, Double-Masked, Placebo-Controlled Study of the Matrix Metalloproteinase Inhibitor AG3340 in Patients with Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration

 

AMD-02-99                                                                                                                                                                    

A Multicenter, Prospective, Randomized, Double-Masked Study Comparing the Safety and Efficacy of Membrane Differential Filtration to a Placebo Treatment in Patients with Non-Exudative Age-Related Macular Degeneration

 

B7A-MC-MBBK

Protein Kinase C Inhibitor ß - Diabetic Macular Edema Study

 

B7A-MC-MBBM                                                                                                              

Protein Kinase C Inhibitor ß - Diabetic Retinopathy Study

 

PDTP-920101-OP004

Phase I/II SnET2 Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration

 

PDTP-920101-OP002                                                                                                                                           

Phase I/II SnET2 Treatment of Subfoveal Choroidal Neovascularization

 

NAVILAS Laser Use in Retinal Tissue 

Navilas laser is a cutting edge technology, which allows for precise placement of laser sport to retinal tissue. During treatment, the computer system will constantly track patient’s eye movement to direct laser spots more precisely than manual delivery.

 

Subvisible Micropulse (SVMP) Laser for Neovascular Age Related Macular degeneration (AMD)

The goal of this study is to evaluate beneficial effects of micropulse laser in treatment of wet macular degeneration. Potential benefits for the patients include less number of injections, faster recovery and better vision.

 

MicroPulse in Retinal Disease 

NRI is on the cutting edge conducting studies evaluating the role of micropulse laser in the treatment of a variety of retinal disorders. Micropulse laser is a gentle laser that does not burn the retina. Instead, it will stimulate the retina to produce beneficial proteins. These proteins in turn will make retina healthier. Numerous studies have shown micropulse laser to be effective for the treatment of a variety of retinal conditions.